Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

NCT00777699 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Non-Small Cell Lung Cancer

Interventions

DRUG: XL765 (SAR245409)
DRUG: erlotinib

Sponsor

Sanofi